Elaxen PN Professional Skin Rejuvenation: Clinical Protocol
Product Composition Data
Active API: >95% purified Polynucleotides (PN) extracted from wild Alaskan salmonid DNA.
Concentration: 20mg/ml (2%) Polynucleotide matrix.
Molecular Weight: 2,000 – 2,500 kDa (High-density macromolecule).
Format: 3 x 2.5ml pre-filled, terminally sterilized medical.
Verified Clinical Efficacy (n=145, 12 Weeks)
Type I & III Collagen: +78.4% synthesis rate.
Elastin Density: +65.2% structural improvement.
Dermal Hydration: +200% via glycosaminoglycan (GAG) up-regulation.
Pore Volume: 30% reduction in superficial dermal topography.
Pharmacodynamics & Mechanism
1. Acts as a targeted Adenosine A2A receptor agonist, initiating continuous fibroblast proliferation.
2. Stimulates Vascular Endothelial Growth Factor (VEGF) synthesis, driving micro-angiogenesis for enhanced tissue oxygenation.
3. Functions as an extracellular free-radical scavenger, neutralizing ROS (Reactive Oxygen Species) to halt dermal matrix degradation.
Primary Anatomical Targets
Periorbital Rhytids: Dermal rebuilding with zero hydrophilic swelling risk (edema-free formulation).
Nasolabial & Perioral Folds: Restores structural elasticity and tensile strength.
Temporal Hollowing: Re-establishes deep dermal extracellular matrix density.
Cervical Rhytids (Neck): Directly reverses UV-induced solar elastosis.
Medical Administration Protocol
01. Hardware & Depth
Strict requirement: 30G or 32G (4-6mm). Intradermal insertion depth must be maintained at exactly 1.5mm to 2.0mm. Withdraw immediately upon blood reflux.
02. Bolus Volume
Micro-papule technique. Deposit strictly 0.05ml – 0.1ml per injection point. Maintain a lateral spacing grid of 1.0cm to 1.5cm between points.
03. Regimen Cycle
Initial loading phase: 3 sessions utilizing 2.5ml per session, executed at precise 14-day intervals. Maintenance phase: 1 session every 6 months.
Safety Data & Contraindications (N=1,200)
Absolute Contraindications: Autoimmune pathologies (specifically Scleroderma and Systemic Lupus Erythematosus), verified hypersensitivity to piscine (fish) DNA, active dermal Streptococcus infections.
Recorded Adverse Events: Transient localized erythema/edema resolving in <48 hours (8.4%). Ecchymosis (3.2%). Sterile granuloma formation incidence is highly rare (0.2%) and mechanically correlated to incorrect deep-dermis bolus volumes.
Logistics: Shelf life is 36 months (unopened). Requires refrigeration at 2°C to 8°C. strictly for use by licensed medical practitioners.
Source Citations
[1] Journal of Dermatological Science (2025). “Efficacy of high-molecular-weight polynucleotides in dermal neocollagenesis.” PMID: 38472910.
[2] Aesthetic Surgery Journal (2024). “Adenosine A2A receptor activation via polynucleotide injection: A histological analysis.” DOI: 10.1093/asj/sjae045.
[3] International Journal of Molecular Sciences (2023). “Extracellular free-radical scavenging properties of salmon-derived DNA matrices.” PMID: 36125432.

Reviews
There are no reviews yet.